Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of entrectinib in advanced or metastatic solid tumors with NTRK, ROS1, or ALK rearrangements
2015-003385-84Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in Nonhematologic neoplasms, sponsored by Roche. Primary endpoint: Objective Response Rate. Started Feb 2016; status: completed.
02
Drugs
entrectinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2015-003385-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003385-84.